Here, we demonstrated the utility of the Akt-FRET biosensor mouse in faithfully reporting on dysregulated AKT activity in a variety of cancer types such as PDAC, where heterozygous loss of PTEN in both a KC and KPC setting up-regulated AKT activity and enhanced disease progression (16). This evidence concerns the gene PTEN and cancer.